Evaluation and comparison of the effectiveness of Hyper CVAD and Arsenic/ interferon/ zidovudine (As/IFN/AZT) treatment regimens in patients with acute Adult T-cell leukemia (ATL).

Start Date25 Mar 2022

Sponsor / Collaborator

Mashhad University of Medical Sciences

EUCTR2019-000910-12-PL

/ CompletedPhase 2

A Double-blinded, Parallel-group, Randomized, Active-controlled Phase 2 Clinical Trial to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous HY-001 Versus Standard Colistin Methanesulfonate Sodium Monotherapy in Patients with Complicated Urinary Tract Infection (with or without pyelonephritis) or Acute Uncomplicated Pyelonephritis at Risk for Infection with Multidrug Resistant Gram-negative Pathogens.

Start Date01 Jul 2020

Sponsor / Collaborator

Helperby Therapeutics Ireland Ltd.

ChiCTR1900026933

/ Not yet recruitingPhase 1IIT

Bioequivalance of Zidovudine and Lamivudine Tablets(Fasting) in the Human Body: A randomized cross-over controlled trial

Start Date28 Oct 2019

Sponsor / Collaborator

Europharm Laboratories Co., Ltd.

100 Clinical Results associated with Zidovudine

100 Translational Medicine associated with Zidovudine

100 Patents (Medical) associated with Zidovudine

13,755

Literatures (Medical) associated with Zidovudine

01 Mar 2026·AIDS

Pubertal onset in children with in-utero HIV/antiretroviral exposure in Botswana

Article

Author: Kgole, Samuel ; Masasa, Gosego ; Shapiro, Roger ; Lockman, Shahin ; Schenkel, Sara ; Kgathi, Coulson ; Serghides, Lena ; Masheto, Gaerolwe ; Powis, Kathleen M. ; Makhema, Joseph ; Williams, Paige L. ; Gochanour, Caroline ; Shaw, Natalie D. ; Phale, Boitshepo ; Ralegoreng, Thuto ; Jao, Jennifer

Objective::

We assessed whether children/adolescents ages 9–11 years with in-utero HIV exposure but uninfected (CAHEU) had a lower chance of pubertal onset compared to children/adolescents who were HIV-unexposed (CAHU) during gestation. Among CAHEU, we assessed the association of in-utero combination antiretroviral therapy (ART) vs. zidovudine monotherapy exposure with pubertal onset.

Design::

An observational cross-sectional study.

Methods::

Pubertal onset (Tanner stage ≥2) was classified by sex and by in-utero HIV exposure status for each puberty indicator (pubic hair, breast development in girls, and male genitalia in boys) among adolescents aged 9–11 years from the Botswana-based FLOURISH study. Logistic regression models were fit to assess the association of in-utero HIV/ARV exposure with pubertal onset, adjusting for age at assessment and potential confounders. Among CAHEU, we compared the occurrence of pubertal onset for ART-exposed vs. zidovudine-exposed.

Results::

We evaluated 325 children/adolescents (228 CAHEU) at median age (IQR) 10.0 years (9.5, 10.6 years). CAHEU had lower mean BMI Z -scores at Tanner assessment (-0.36 vs. 0.19) than CAHU. While female CAHEU had higher odds of pubertal onset by pubic hair compared with female CAHU (adjusted odds ratio=2.75, 95% confidence interval: 1.04–7.30), no other differences in pubertal onset were observed by in-utero HIV exposure. Among CAHEU, no differences in pubertal onset by in-utero exposure to ART vs. zidovudine were observed.

Conclusion::

In this small Botswana cohort, we observed no consistent differences in pubertal onset by in-utero HIV exposure status or by in-utero antiretroviral exposure. Longitudinal studies are needed to confirm these findings.

01 Feb 2026·HARMFUL ALGAE

Environmentally relevant concentrations of the antibiotic azithromycin enhance the toxicity of the cyanobacterium Microcystis aeruginosa on the water flea Daphnia similis

Article

Author: Azevedo, Sandra Maria Feliciano de Oliveira E ; Vilar, Mauro Cesar Palmeira ; Celano, Michael Ribas ; De Pinho, Júlia Vianna

Artificial eutrophication has degraded water bodies worldwide, promoting harmful cyanobacterial blooms (CyanoHABs). In addition to nutrient loading, antibiotics are increasingly being introduced into aquatic environments, exacerbating water pollution, and the impact on biota. Among antibiotics, azithromycin (AZT) has displayed a rise in environmental occurrence following its increased global consumption during the COVID-19 pandemic. Therefore, we assessed the effect of environmentally relevant concentrations of AZT (≤3 μg l^-1) on the interaction between the toxic cyanobacterium Microcystis aeruginosa and the freshwater zooplankton Daphnia similis. The acute toxicity of both the cyanobacterium and antibiotic on Daphnia was determined, followed by an herbivory and a life-table assay to assess behavioral and sublethal effects under single and combined exposures. The 96-hour LC₅₀ and EC₅₀ for AZT were 35.2 and 29.1 mg l^-1, respectively. The risk quotient for D. similis was 0.098, indicating a low ecological risk (RQ < 0.1). Regarding M. aeruginosa, 96-hour LC₅₀ and EC₅₀ values were 713 and 303 μgC l^-1, respectively, with RQ values >700, indicating a high ecological risk. Environmental levels of AZT did not affect Daphnia, while the cyanobacterium inhibited zooplankter feeding and life-table responses. However, combined exposure to AZT and toxic M. aeruginosa resulted in a greater decrease in survival and overall population fitness, besides an increased cyanobacterial ingestion. These findings suggest that environmental concentrations of AZT may intensify the impacts of toxic cyanobacteria on zooplankton. This highlights the need for further research into the mechanisms underlying the enhanced toxicity of cyanobacteria promoted by antibiotics at environmental levels.

01 Feb 2026·JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Low Levels of Clinically Significant Drug Resistance Mutations to Dolutegravir Among Children Living with HIV Failing on First-Line Antiretroviral Therapy in Uganda

Article

Author: Twinomujjuni, Evarist ; Senyama, George ; Nkolo, Esther ; Nabitaka, Vennie ; Nazziwa, Esther ; Dowling, Stephanie ; Nakanwagi, Miriam ; Alwano, Mary ; Nzano, Brian ; Hast, Marisa ; Ayitewala, Alisen ; Namayanja, Grace ; Nakaweesi, Jane ; Hackett, Stephanie ; Magongo, Eleanor N.

Background::

Introduction of pediatric-friendly dolutegravir (DTG) formulations to treat children living with HIV (CLHIV) has presented new opportunities to improve viral suppression; however, there are limited data on emerging patterns of HIV drug resistance (HIVDR) in this population.

Methods::

We identified CLHIV aged 0–15 years experiencing virologic failure on first-line antiretroviral therapy in Uganda between January 2021 and November 2021 from the Central Public Health Laboratory database. Remnant viral load samples were tested for HIVDR using Sanger sequencing. Drug resistance mutations (DRMs) were identified, and antiretroviral susceptibility was interpreted using the Stanford University HIVDR Database algorithms. The prevalence of DRMs and HIVDR is summarized using descriptive statistics, and associations with demographic and clinical factors were determined using χ 2 tests.

Results::

Among 333 successfully genotyped patient samples, 122 (36.6%) CLHIV were on a DTG-based regimen and 136 (40.8%) on a lopinavir-based regimen. Among all CLHIV, 271 (81.4%) had DRMs and 262 (78.7%) had any intermediate-to-high level HIVDR [including DTG (1.8%), lopinavir (9.6%), abacavir (ABC) (25.5%), and zidovudine (19.2%)]. Among CLHIV on a DTG-based regimen, 6.6% had any integrase inhibitor DRMs and 4.1% had intermediate-to-high resistance to DTG. Children on DTG-based regimens were less likely to have DRMs ( P = 0.007) or HIVDR ( P = 0.02) compared with all other regimens. CLHIV on DTG-based regimens with an ABC backbone were no more likely to have DRMs ( P = 0.9) or HIVDR ( P = 0.5) compared with those with a backbone not containing ABC.

Conclusions::

Low rates of DTG resistance among Ugandan CLHIV failing first-line DTG-based antiretroviral therapy regimens underscore the durability of DTG. Lack of difference in ABC resistance across all regimens supports maintaining an ABC backbone for CLHIV <30 kg when transitioning to a DTG-based regimen despite virologic failure.

News (Medical) associated with Zidovudine

20 Jan 2026

·www.biopharmadive.com

GSK to buy Rapt in $2.2B deal for food allergy drug

Dive Brief:GSK on Tuesday said its agreed to buy Rapt Therapeutics for $2.2 billion, gaining access to a drug that promises to help a wider population of patients avoid allergic reactions to food.The medicine, ozureprubart, targets the immunoglobulin E, or IgE antibodies that are produced when a patients immune system overreacts after encountering allergens. Once released, the IgE antibodies help trigger allergic reactions that can sometimes be deadly for patients.Ozureprubart is currently in Phase 2b testing, and Rapt believes it has the potential to be administered every eight to 12 weeks, instead of the two-to-four week regimens currently used for Roche and Novartis Xolair. The company also expects the drug to be used by a bigger pool of patients, including those with high levels of IgE or a body weight that makes them ineligible to take Xolair.Dive Insight:The Rapt deal offers the potential of another blockbuster to beef up the British drugmakers retrenched pipeline. Former CEO Emma Walmsley, who had run GSK since April 2017, stepped down at the end of last year after streamlining the business and focusing it more on oncology and innovative medicines.Through much of Walmsleys tenure, GSK faced pressure from investors who believed that the company was underperforming rivals. Traditionally a powerhouse in vaccines, GSK opted not to develop its own shot during the COVID-19 pandemic and partnerships with other vaccine makers stumbled. Meanwhile, the maker of AZT faced pressure on its pioneering HIV business as patent losses loomed.The last year, however, saw a turnaround for GSK. The companys shares have jumped about 42% over the last 12 months in New York trading, far outpacing the 26% climb in the S&P 500 Pharmaceuticals Index. Major drug approvals helped, including wins for a multiple myeloma medicine and a twice-yearly asthma treatment billed as a potential change in standard of care.And just this month, GSK announced promising results for an experimental hepatitis B treatment. The companys chief scientific officer, Tony Wood, highlighted that drug recently when he told investors GSK aims to launch 15 medicines with peak sales potential of more than $2 billion each in the coming years.The Rapt drug fits into that vision for future blockbusters. In the U.S. alone, more than 17 million people suffer from food allergies, causing some 3 million visits to hospitals and emergency care centers. Effective drugs to prevent allergic reactions could compete in a market worth $10 billion or more, Jefferies analyst Michael Leuchten wrote in a note to clients.Ozureprubart may end up being a multi-blockbuster opportunity for food allergy treatment as well as other indications linked to IgE, Leerink Partners analyst Thomas Smith wrote in a separate note. The deal is a strong strategic fit for GSK, he added.For Rapt, the GSK deal caps an unlikely turnaround. The company abandoned its previous lead drug amid safety concerns and later had to cut staff twice. As late as July of last year, Rapt shares were trading below $8. But promising early results for ozureprubart, licensed from China in late 2024, changed its fortunes. On Tuesday, Rapt shares soared close to the GSK offer price of $58.The companies expect the deal to close in the first quarter of this year. '

Phase 2VaccineAcquisitionPhase 3Executive Change

30 Dec 2024

·pharma.economictimes.indiatimes.com

'Breakthrough of the Year' drug for HIV care

New Delhi: Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug Administration ( FDA ) approving lenacapavir, a new prototype medication. It uses a unique mechanism of twice-yearly injections to treat individuals with multidrug-resistant HIV. The development of lenacapavir by Gilead Sciences has been described by the journal Science as the 2024 Breakthrough of the Year. It noted that it was "a pivotal step toward diminishing HIV/AIDS as a global health crisis." The introduction of lenacapavir is potentially a major step forward in the treatment of HIV/AIDS globally. It could help achieve UN Sustainable Development Goal 3 which sets the target of eliminating HIV/AIDS as a public health threat and moving towards a sustainable HIV response beyond 2030. The breakthrough comes at a time when HIV/AIDS remains a formidable challenge in global public health since it was discovered in the early 1980s. Initially identified in the United States, HIV/AIDS has since claimed more than 42 million lives worldwide and infected more than 88 million people. There were 39.9 million people living with AIDs globally at the end of 2023. While advancements in antiretroviral therapy (ART, a combination of HIV medicines that treats people infected with the virus) have transformed the management of HIV, it continues to pose significant challenges, particularly for individuals with multidrug-resistant strains of the virus. HIV originated from zoonotic transmission, likely jumping from non-human primates to humans in Central and West Africa in the early 20th century. However, it was not until 1983 that French researchers identified the virus responsible for what later became known as AIDS (acquired immunodeficiency syndrome). This marked the start of a global fight against a virus that devastates the immune system, leaving individuals vulnerable to opportunistic infections and certain cancers. Antiretroviral therapy, first introduced with the FDA's approval of AZT in 1987, was a turning point in HIV treatment. Over 50 antiretroviral drugs are now FDA-approved, offering a range of options to manage the virus effectively. Despite these advances, HIV remains incurable, and many patients face challenges such as drug resistance, requiring new therapeutic innovations. To understand the impact of HIV, it helps to compare it with the recent COVID-19 pandemic. COVID-19, largely preventable through vaccines and treatments, differs from AIDS, which remains incurable and can only be managed with antiretroviral therapies. COVID-19 spread rapidly, causing over seven million deaths worldwide in a short time. Respiratory viruses like SARS-CoV-2 that caused COVID-19 are well-studied, and the targets of vaccine development well characterised. In contrast, HIV's high mutation rate, integration into human DNA, and long latency period have made vaccine development extremely challenging. Unlike COVID-19, which mainly causes acute illness, HIV gradually weakens the immune system, leading to chronic vulnerability to infections like tuberculosis, resulting in far higher mortality rates. Efforts to combat HIV are further complicated by stigma and discrimination, particularly among marginalised communities. It has been estimated that sub-Saharan Africa, which accounts for 15 per cent of the global population, has two-thirds of the people living with HIV. About 4,000 teen girls and young women are newly infected with HIV every week (2022 figures). In this context, the FDA's approval of lenacapavir, a first-in-class drug designed for individuals with multidrug-resistant HIV, is indeed a breakthrough. Lenacapavir's efficacy was demonstrated through extensive clinical trials conducted globally, including in many countries in Latin America, South Africa, Thailand and the United States. The details of the clinical trials study (called PUPOSE 2) conducted by Gilead state, "Lenacapavir was highly effective at reducing HIV infections among trial participants: 99.9% of participants did not acquire HIV in the lenacapavir group, with two incident cases among 2,179 participants (0.10/100 person-years, 95% CI, 0.01 to 0.37)." This, the study claimed, was despite reported high levels of sexual behavior, chemsex and sexually transmitted infections observed among PURPOSE 2 participants. The trials highlighted its potential to significantly reduce viral loads, particularly in patients who had exhausted other treatment options. Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. The procedure for administering lenacapavir involves an initial oral loading dose, followed by subcutaneous injections every six months. Lenacapavir works by targeting the HIV capsid, a protein shell that protects the virus's genetic material. The drug is not a standalone therapy and must be used in combination with other antiretroviral medications to ensure comprehensive viral suppression. Because of its innovative mechanism and extended dosing schedule it has been described as a pathbreaking advancement in HIV care and is being heralded as an early vaccine-like innovation in HIV treatment, providing extended viral suppression that minimises daily treatment burdens. This simplified regimen improves adherence and reduces the risk of treatment failure due to missed doses. However, a major challenge in the widespread use of lenacapavir particularly in low- and middle-income countries which have high loads of HIV infections is mainly due to its current cost. Early pricing has indicated significant disparities, which have led to calls for subsidies and international collaboration to make the drug accessible to those who need it most. Already, the Global Fund to Fight AIDS has joined hands with several other foundations for a coordinated effort to provide affordable and equitable access to the twice-yearly injectable drug. This would be subject to "regulatory approval from the U.S. Food and Drug Administration, relevant national pharmaceutical regulators, and a recommendation from the World Health Organization (WHO)." However, the FDA has now approved the drug. Lenacapavir has also been approved in several countries to treat adults who have multiple drug-resistant HIV, to be used along with other antiretroviral drugs. There are indications that the drug can also prevent new HIV infections. In October this year, Gilead announced that it has "signed non-exclusive, royalty-free voluntary licensing with six pharmaceutical companies to manufacture and supply high-quality, low-cost versions of lenacapavir for HIV prevention for 120 primarily low- and lower-middle-income countries." While the development of lenacapavir is a major innovative step forward in the fight against HIV, it also underscores the importance and need for continued research for more efficacious therapies against HIV including anti-HIV vaccine innovation, and equitable healthcare policies. The fight against HIV continues, but lenacapavir offers promise for improved management of the infection. (360info.org) GSP

Drug ApprovalVaccineClinical StudyImmunotherapy

15 Oct 2024

·www.prnewswire.com

WARBURG PINCUS STRENGTHENS ITS EUROPEAN BUSINESS AND GLOBAL HEALTHCARE GROUP WITH TWO NEW SENIOR ADVISERS

Seasoned industry experts will advise Warburg Pincus on new investments and drive value creation across its portfolio companies LONDON and BERLIN, Oct. 15, 2024 /PRNewswire/ -- Warburg Pincus, a leading global growth investor, today announced the appointment of Dr. Francesco Granata and Dr. Axel Herberg as Senior Advisers working with its European business and global healthcare group. Dr. Granata and Dr. Herberg will support Warburg Pincus in the identification and evaluation of new potential investment opportunities across Europe for its funds, and they bring deep expertise and connectivity within the pharmaceutical, life sciences, medical device and healthcare sectors. The senior adviser appointments follow the recent announcement of Enovo Life Sciences, a new life sciences platform institutionally capitalized by funds advised by Warburg Pincus and led by life sciences industry veterans, Mario Philips and Roel Gordijn. These announcements demonstrate the continued momentum in Warburg Pincus's European business. Jake Strauss, a Managing Director in the global healthcare group, was recently announced as head of the firm's European healthcare efforts and Tobias Weidner, recently joined the firm as a Managing Director leading industrials in Europe. Recent European investments include Aztec, Specialist Risk Group and Epassi. Dr. Herberg brings wide-ranging experience as an operator and investor. He is a member of various supervisory boards and is an active entrepreneur. He joined the Gerresheimer Group in 1992 and developed the company to a leading systems and solutions provider to the pharma and biotech industries and is currently Chairman of the Supervisory Board. Between 2010 and 2017, Dr. Herberg was a Partner at Blackstone, responsible for the private equity business in the German-speaking regions of Europe. Dr Herberg currently sits on the boards of Gerresheimer, Axplora, and Vetter Pharma. Dr. Granata has more than 40 years of experience in the pharmaceuticals and biotechnology industries. He was Executive Vice President and member of the Executive Committee at Biogen Idec; served as Group Vice President at Schering-Plough, and President of Schering-Plough Europe and Canada; and held various senior management positions at Pharmacia, Dompé Biotech, and Pfizer. He currently sits on the Boards of Italfarmaco and GreenBone Ortho. He is General Partner and co-founder of Venture Capital firm 3B Future. Jake Strauss, Managing Director at Warburg Pincus, said, "We are excited to be working with Francesco and Axel. They bring decades of invaluable experience and strong networks across Europe that will further enhance our ability to identify attractive investment opportunities for our funds where we can partner with management teams, entrepreneurs, and families to accelerate growth. Their experience will also be invaluable to our existing portfolio companies in allowing them to navigate the complex macroeconomic and technological drivers of change that are transforming their industries." Dr Axel Herberg said, "I am looking forward to working with the exceptional team at Warburg Pincus. The firm's strong reputation, deep sector expertise and recent growth in Europe, make this an exciting time to work with the European team." Dr Francesco Granata said, "Warburg Pincus has a long history of successfully partnering with founders and management teams and bringing deep expertise to help businesses build long-term sustainable growth. I look forward to working together to identify exciting new businesses and strong management teams driving innovation, technological change and improved patient outcomes across the healthcare sector." Funds advised by Warburg Pincus have been among the leading global growth investors in Europe and were one of the first to invest in Europe in 1983. In Europe, the Warburg Pincus funds have invested more than $14 billion in over 125 companies across more than 20 European countries. Warburg Pincus funds have invested over $18 billion in more than 189 innovative healthcare and life sciences companies around the world, including Bausch + Lomb, Ensemble Healthcare Partners, Global Healthcare Exchange, Modernizing Medicine, and Sotera Health. The firm has also notably been active in the European healthcare market including recent investments by the funds in Polyplus, Simtra BioPharma Solutions, Norstella and the START Center for Cancer Research. About Warburg Pincus Warburg Pincus LLC is a leading global growth investor. The firm has more than $83 billion in assets under management. The firm's active portfolio of more than 225 companies is highly diversified by stage, sector, and geography. Warburg Pincus is an experienced partner to management teams seeking to build durable companies with sustainable value. Since its founding in 1966, Warburg Pincus has invested more than $117 billion in over 1,000 companies globally across its private equity, real estate, and capital solutions strategies. The firm is headquartered in New York with offices in Amsterdam, Beijing, Berlin, Hong Kong, Houston, London, Luxembourg, Mumbai, Mauritius, San Francisco, São Paulo, Shanghai, and Singapore. For more information please visit . Follow us on LinkedIn. Media Contact Jenna Ward, Europe Communications Director M: +44 7570 844 338 E: [email protected] WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Executive Change

100 Deals associated with Zidovudine

External Link

KEGG	Wiki	ATC	Drug Bank
D00413	Zidovudine	J05AF01	DB00495

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	19 Mar 1987

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	United States	Glaxo Wellcome SA	31 Aug 2001
Pregnancy	Phase 3	Puerto Rico	Glaxo Wellcome SA	31 Aug 2001
Toxoplasmosis, Cerebral	Phase 1	United States	Glaxo Wellcome SA	31 Aug 2001
Acquired Immunodeficiency Syndrome	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
Acquired Immunodeficiency Syndrome	Clinical	Puerto Rico	Glaxo Wellcome SA	31 Aug 2001
AIDS Dementia Complex	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
AIDS-Related Complex	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
AIDS-Related Complex	Clinical	Puerto Rico	Glaxo Wellcome SA	31 Aug 2001
HIV Seropositivity	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001
Kidney Failure, Chronic	Clinical	United States	Glaxo Wellcome SA	31 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2025	Not Applicable	Adult T-Cell Leukemia-Lymphoma	177	CHOP	mlarulhrtj(lyuyjigehg) = hzkwkgdztd seifegwimm (fdjtrnnmzz ) View more	Negative	06 Dec 2025
NCT02737046 (ASH2025)	Phase 2	Adult T-Cell Leukemia-Lymphoma	15	AI-BEL (AZT/Interferon-α plus Belinostat)	rpnthzpcqm(zpsndxapdh) = yuxlqqbufr vplxkgiehp (ydpzaiidfx ) View more	Positive	06 Dec 2025
NCT03988452 (NADIA, Pubmed \| Lancet HIV)	Phase 3	HIV Infections Second line	465	Dolutegravir	mfbligubek(zcakvhlhmm) = cxjwcifkbq luisqwrcue (hgpnwoxpwh )	Positive	20 Apr 2022
				Ritonavir-boosted darunavir	mfbligubek(zcakvhlhmm) = knyiuubgdm luisqwrcue (hgpnwoxpwh )
NCT01818258 (IMPAACT P1092, CTgov)	Phase 4	Malnutrition \| HIV Infections	52	Zidovudine+Lamivudine+Lopinavir/Ritonavir (Severe Malnutrition)	ffmqweeabd(bzjeaaojvh) = kjgnugvvqo huodjiclxj (chkrmrjalc, gbszxwbvrj - ngbrlwstcw) View more	-	12 Aug 2021
				Zidovudine+Lamivudine+Lopinavir/Ritonavir (Normal Nutrition/Mild Malnutrition)	ffmqweeabd(bzjeaaojvh) = khahonzkes huodjiclxj (chkrmrjalc, ssscpbdjmv - kblhrqaewt) View more
NCT02369406 (Early Infant Treatment Study in Botswana, Pubmed \| Clin Infect Dis)	Phase 2/3	-	40	Nevirapine (NVP), Zidovudine (ZDV), and Lamivudine (3TC)	jxfawaspda(pqfcazggzw) = yzoyvefwxk fcazynrlse (omjqvinbzk ) View more	Positive	01 Feb 2021
				Lopinavir-ritonavir (LPV-r)	jxfawaspda(gbqdwcqmxl) = dzoxkzinmz jxvrsvpkmc (miwusqzhkl )
NCT01441063 (CTgov)	Phase 2	Multi-Centric Castleman's Disease	8	Tocilizumab (Tocilizumab Monotherapy)	nnjfrsofyh = gjdenhaesi wucpoaxaeg (fwhdvmmvwu, nowwtiuwob - wpwpxozsan) View more	-	23 Jun 2020
				Tocilizumab (Tocilizumab Combination Therapy)	nnjfrsofyh = uvtastsoqh wucpoaxaeg (fwhdvmmvwu, vzjoixjswe - nbxbtuslnm) View more
NCT01386970 (CTgov)	Phase 4	HIV Infections	43	zidovudine+Combivir+lamivudine (HIV-negative)	foaflzmsyg(ausnxnvvqp) = piruikcdaw auylgvuwzb (jsrjmxikfq, qvvtzlxksi - gpvvrmjqxn) View more	-	16 Mar 2020
				zidovudine+Combivir+lamivudine (HIV-infected)	foaflzmsyg(ausnxnvvqp) = wlvjewpbek auylgvuwzb (jsrjmxikfq, lbupqokpsg - vyngdeyuxk) View more
NCT01964755 (CTgov)	Phase 2	Post-transplant lymphoproliferative disorder \| Acquired Immunodeficiency Syndrome \| Epstein-Barr virus associated Hodgkin's Lymphoma ... View more	6	Zidovudine+Leucovorin+Doxorubicin+hydroxyurea+Methotrexate+Rituximab	kuaqkdzyus = dhjasjzxjm eygtofqivj (fpdfqomjao, koysthqyub - hfhejbaxvk) View more	-	23 Sep 2019
NCT00102960 (CHER, CTgov)	Phase 3	HIV Infections	377	Zidovudine+Abacavir sulfate+Didanosine+Efavirenz+Lamivudine+Nevirapine+Lopinavir/Ritonavir	ywkysvgbxf = ocbznehxdk oqpsgkcesn (citdjjfmzi, vekjwggshr - dppaajabvd)	-	30 Nov 2018
NCT00993031 (PROMOTE-PIs \| Prevention of Malaria and HIV Disease in Tororo trial \| PROMOTE \| PROMOTE-Pregnant Women and Infants Study, CTgov)	Phase 3	HIV Infections \| Malaria	389	Zidovudine+Lamivudine+Lopinavir/ritonavir (Group A)	kaiuajlkko = bslnewiafc xpsasakfxs (dzkkuhlshx, xqumemdwwb - cyzbvshwlb) View more	-	02 Dec 2017
				Zidovudine+Efavirenz+Lamivudine (Group B)	kaiuajlkko = rgglxghzdy xpsasakfxs (dzkkuhlshx, kpauhaesse - hkudnntinb) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis